Scientific Publications

The following list contains some of the key scientific articles that were published in peer-reviewed journals.

  1. Caluwaerts S, Vandenbroucke K, Steidler L, Neirynck S, Vanhoenacker P, Corveleyn S, Watkins B, Sonis S, Coulie B, Rottiers P. AG013, a mouth rinse formulation of Lactococcuslactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncology, accepted for publication
  2. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 2010 Jan;3(1):49-56.
  3. Rottiers P, De Smedt T, Steidler L. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int Rev Immunol. 2009;28(6):465-86
  4. Steidler L, Rottiers P, Coulie B. . Actobiotics as a novel method for cytokine delivery. Ann N Y Acad Sci. 2009 Dec;1182:135-45.
  5. Loos M, Remaut E, Rottiers P, De Creus A. Genetically engineered Lactococcus lactis secreting murine IL-10 modulates the functions of bone marrow-derived dendritic cells in the presence of LPS. Scand J Immunol. 2009 Feb;69(2):130-9.
  6. Huibregtse IL, Marietta EV, Rashtak S, Koning F, Rottiers P, David CS, van Deventer SJ, Murray JA. Induction of antigen-specific tolerance by oral administration of Lactococcus lactis-delivered immunodominant DQ8-restricted gliadin peptide in sensitized non-obese diabetic abdegrees Dq8 transgenic mice. Journal of Immunology 2009; 183(4):2390-6
  7. Van Huynegem K, Loos M, Steidler L. Immunomodulation by genetically engineered lactic acid bacteria. Frontiers in Bioscience 2009; 1(14):4825-35
  8. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nature Reviews Microbiology 2008; published online March 17th
  9. Waeytens A, Ferdinande L, Neirynck S, Rottiers P, De Vos M, Steidler L, Cuvelier C. Paracellular entry of Interleukin-10 producing Lactococcus lactis in inflamed intestinal mucosa in mice. Inflammatory Bowel Disease 2008; 14(4):471-9
  10. Frossard CP, Steidler L, Eigenmann PA. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. Journal of Allergy and Clinical Immunology 2007; 119, 952-959
  11. Huibregtse IL, Snoeck V, De Creus A, Braat H, De Jong EC, Van Deventer SJH, Rottiers P. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 2007; 133(2), 517-528
  12. Steidler L & Rottiers P. Therapeutic drug delivery by genetically modified Lactococcus lactis. In: Inflammatory Bowel Disease: Genetics, Barrier Function, Immunologic Mechanisms, and Microbial Pathways, Annals of the New York Academy of Sciences 2006; Vol. 1072, 176-186
  13. Steidler L & Vandenbroucke K. Genetically modified Lactococcus lactis: novel tools for drug delivery. International Journal of Dairy Technology 2006; 59, 140-146
  14. Termont S, Vandenbroucke K, Iserentant D, Neirynck S, Steidler L, Remaut E, Rottiers P. Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance. Applied and Environmental Microbiology 2006; 72(12), 7694-7700
  15. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, Van Deventer SJH, Neirynck S, Peppelenbosch MP, Steidler L. A Phase I trial with transgenic bacteria expressing Interleukin-10 in Crohn's disease. Clinical Gastroenterology and Hepatology 2006; 4(6), 754-759
  16. Remaut E, Braat H, Vandenbroucke K, Rottiers P, Steidler L. Clinical potential of Lactococcus lactis mediated delivery of human Interleukin-10 and Trefoil Factors. Bioscience Microflora 2006; 25, 81-97
  17. Steidler L, Rottiers P. Therapeutic drug delivery by genetically modified Lactococcus lactis. Ann N Y Acad Sci 2006; 1072, 176-186. Neirynck S & Steidler L. Delivery of therapeutic proteins through Lactococcus lactis. Biotechnol Genet Eng Rev. 2006;22, 253-266.
  18. Huyghebaert N, Vermeire A, Rottiers P, Remaut E, Remon JP. Development of an enteric-coated, layered multi-particulate formulation for ileal delivery of viable recombinant Lactococcus lactis. European Journal of Pharmaceutics and Biopharmaceutics 2005; 61(3), 134-141
  19. Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP. Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis. European Journal of Pharmaceutics and Biopharmaceutics 2005; 59, 9-15
  20. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004; 127(2), 502-513
  21. Steidler L. Live genetically modified bacteria as drug delivery tools: at the doorstep of a new pharmacology? Expert Opinion on Biological Therapy 2004; 4, 439-441
  22. Steidler L. Genetically engineered probiotics. Best Practice & Research in Clinical Gastroenterology 2003; 17, 861-876
  23. Steidler L & Neirynck S. In situ delivery of therapeutic proteins by recombinant Lactococcus lactis. Journal of Microbiology 2003; 41, 63-72
  24. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human Interleukin-10. Nature Biotechnology 2003; 21(7), 785-789
  25. Steidler L. Microbiological and immunological strategies for treatment of inflammatory bowel disease. Microbes and Infection 2001; 3, 1157-1166
  26. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting Interleukin-10. Science 2000; 289(5483), 1352-1355
  27. Steidler L, Robinson K, Chamberlain L, Schofield KM, Remaut E, Le Page RWF, Wells JM. Mucosal delivery of murine Interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis co-expressing antigen and cytokine. Infection and Immunity 1998; 66, 3183-3189